NCT02564367 - Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2015

Primary Completion Date

March 1, 2019

Study Completion Date

March 6, 2020

Conditions

Adenocarcinoma,StomachAdenocarcinoma, Esophagogastric Junction

Interventions

DRUG

S-1

"18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks"

Trial Locations (1)

Unknown

Klinikum der Universität München, Campus Großhadern, München